SRRK on Nasdaq

Scholar Rock Holding Corp

We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and additional rare, severe and debilitating neuromuscular.5 From its latest annual report

$40.78 up 1.18 (2.98%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 19, 2026.

Overview

Compare with Precision BioSciences, X4 Pharmaceuticals, Inc or C4 Therapeutics (United States), or pick any stock.

  • TickerSRRK on Nasdaq2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersCambridge, United States2
  • Incorporated inDE4
  • Business address301 Binney Street, 3Rd Floor, Cambridge, Ma 021424
  • Filer categoryNon-accelerated filer4
  • Legal formCorporation2
  • LEI549300Z1FLPGL4OWJ4592
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressCORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 66674512

See how the biggest companies compare on our leaderboards

We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and additional rare, severe and debilitating neuromuscular diseases. As a leader in the biology of the transforming growth factor beta (“TGFβ”) superfamily, our novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Based on our innovative, proprietary, and scalable technology platform, we are building a world-leading anti-myostatin pipeline. During 2025, we made significant progress in advancing our product candidates. We believe 2026 could be a transformational year for Scholar Rock as we anticipate the potential to become a commercial-stag…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-154.0%Return on equity6
0.41×Debt to equity6
-$300.6MFree cash flow6

Financial statements

Revenue789106$0 in 2025
0$10.0M$20.0M$30.0M$40.0M2019: $20.5M$20.5M20192020: $15.4M$15.4M2020−25%2021: $18.8M$18.8M2021+22%2022: $33.2M$33.2M2022+76%2025: $0$02025
Operating income78910116-$384.6M in 2025+605% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$54.5M-$54.5M20192020: -$86.9M-$86.9M2020+59%2021: -$129.9M-$129.9M2021+50%2022: -$134.4M-$134.4M2022+3%2023: -$171.3M-$171.3M2023+27%2024: -$252.1M-$252.1M2024+47%2025: -$384.6M-$384.6M2025+53%
Net income78910116-$377.9M in 2025+641% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$51.0M-$51.0M20192020: -$86.5M-$86.5M2020+70%2021: -$131.8M-$131.8M2021+52%2022: -$134.5M-$134.5M2022+2%2023: -$165.8M-$165.8M2023+23%2024: -$246.3M-$246.3M2024+49%2025: -$377.9M-$377.9M2025+53%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Research and development$208.4M$184.6M
General and administrative$176.2M$67.5M
Total operating expenses$384.6M$252.1M
Loss from operations-$384.6M-$252.1M
Interest income$13.9M$12.7M
Interest expense-$6.9M-$6.8M
Other expense, net-$301.0K-$85.0K
Total other income (expense), net$6.7M$5.8M
Net loss per share, basic (in dollars per share)-$3.29-$2.47
Net loss per share, diluted (in dollars per share)-$3.29-$2.47
Weighted average common shares outstanding, basic (in shares)114.7M shares99.8M shares
Weighted average common shares outstanding, diluted (in shares)114.7M shares99.8M shares
Net loss-$377.9M-$246.3M
Unrealized gain (loss) on marketable securities-$64.0K$68.0K
Foreign currency translation adjustments-$2.0K
Total other comprehensive income (loss)-$66.0K$68.0K
Comprehensive loss-$378.0M-$246.2M

Compare Scholar Rock Holding Corp with another company

Leadership

Who has led Scholar Rock Holding Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nagesh K. Mahanthappa2018–2022
  2. Stuart A. Kingsley2020–2021
  3. Jay T. Backstrom2022–2025
  4. David Hallal2025–now

President

  1. Nagesh K. Mahanthappa2018–2022
  2. Stuart A. Kingsley2020–2021
  3. Akshay Vaishnaw2025–now

Chief financial officer

  1. Rhonda M. Chicko2018–2019
  2. Edward H. Myles2020–2025
  3. Vikas Sinha2025–now

Chief operating officer

  1. Elan Ezickson2018
  2. Edward H. Myles2022–2025
  3. Keith Woods2025–now
20202025
Board members and other officers (24)

Timeline

  1. Apr 29, 2025New chief executive David Hallal becomes CEO14
  2. Sep 22, 2022New chief executive Jay T. Backstrom becomes CEO15
  3. Jul 17, 2020New chief executive Stuart A. Kingsley becomes CEO16
  4. May 23, 2018New chief executive Nagesh K. Mahanthappa becomes CEO17
  5. Dec 31, 2016Founded Scholar Rock Holding Corp is founded2

Filings

438 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 65 major events, 231 insider forms, 47 large holders, 75 other. The latest 20:

  1. Oct 1, 2026144 EDGAR
  2. Sep 25, 20264 OWNERSHIP DOCUMENT EDGAR
  3. Sep 23, 20264 OWNERSHIP DOCUMENT EDGAR
  4. Sep 15, 20268-K EDGAR
  5. Sep 14, 20268-K EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 13, 2026SCHEDULE 13G/A EDGAR
  8. Aug 6, 202610-Q EDGAR
  9. Aug 6, 20268-K EDGAR
  10. Aug 6, 20268-K EDGAR
  11. Aug 6, 2026424B5 EDGAR
  12. Jul 6, 2026144 EDGAR
  13. Jul 6, 20264 EDGAR
  14. Jul 6, 20264 EDGAR
  15. Jul 6, 20264 EDGAR
  16. Jul 6, 20264 EDGAR
  17. Jul 6, 20264 EDGAR
  18. Jul 1, 2026144 EDGAR
  19. Jul 1, 2026144 EDGAR
  20. Jul 1, 2026144 EDGAR

The 438 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

109 open-market trades by officers, directors and large owners since October 2021: 12 buys and 97 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2026FLIER JEFFREY S.DirectorSale3,053$53.88$164.5KForm 4
Jul 1, 2026Gilman MichaelDirectorSale2,544$53.87$137.1KForm 4
Jul 1, 2026Burow KristinaDirectorSale3,053$53.74$164.1KForm 4
Jul 1, 2026Reed JoshuaDirectorSale3,053$53.74$164.1KForm 4
Jul 1, 2026Peng KatieDirectorSale5,446$53.87$293.4KForm 4
Apr 16, 2026Woods KeithChief Operating OfficerSale10,220$49.57$506.6KForm 4
Apr 16, 2026Vaishnaw AkshayPresident of R&DSale12,246$49.57$607.0KForm 4
Apr 16, 2026Sinha VikasChief Financial OfficerSale10,410$49.57$516.0KForm 4
Apr 16, 2026Hallal DavidChief Executive OfficerSale30,615$49.57$1.5MForm 4
Feb 23, 2026Qatanani MoCHIEF SCIENTIFIC OFFICERSale8,484$47.07$399.3KForm 4
Feb 17, 2026Qatanani MoCHIEF SCIENTIFIC OFFICERSale7,989$46.53$371.7KForm 4
Feb 17, 2026Parlavecchio CarynCHROSale9,035$46.53$420.4KForm 4
Feb 17, 2026Ho JunlinGENERAL COUNSELSale9,580$46.53$445.8KForm 4
Feb 17, 2026Marantz Jing L.CHIEF MEDICAL OFFICERSale4,157$46.53$193.4KForm 4
Jan 22, 2026Qatanani MoCHIEF SCIENTIFIC OFFICERSale14,898$46.71$695.9KForm 4
Jan 16, 2026Qatanani MoCHIEF SCIENTIFIC OFFICERSale8,406$44.48$373.9KForm 4
Jan 16, 2026Parlavecchio CarynCHROSale6,600$44.48$293.6KForm 4
Jan 16, 2026Ho JunlinGENERAL COUNSELSale8,016$44.48$356.6KForm 4
Jan 16, 2026Marantz Jing L.CHIEF MEDICAL OFFICERSale5,798$44.48$257.9KForm 4
Jan 14, 2026Qatanani MoCHIEF SCIENTIFIC OFFICERSale13,112$45.20$592.7KForm 4

All 109 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC17,995,241$989.7M0.0%+752,089
Siren, L.L.C.9,575,013$526.6M10.7%−1,250,000
BlackRock, Inc.9,494,084$522.2M0.0%+2,024,791
Samsara Biocapital, LLC6,897,652$379.4M31.2%No change
Wellington Management Group Llp6,727,085$370.0M0.1%+9,430
Orbis Allan Gray Ltd5,933,533$326.3M1.1%+1,753,550
Vanguard Capital Management LLC4,767,880$262.2M0.0%+876,533
State Street Corp4,728,681$260.1M0.0%+697,364
Redmile Group, LLC4,311,092$237.1M15.9%−4,755,529
Norges Bank2,769,910$152.3M0.0%New
Geode Capital Management, LLC2,753,787$151.5M0.0%+604,751
Massachusetts Financial Services Co /ma/2,607,348$143.4M0.0%New
Bellevue Group AG2,449,547$134.7M2.8%−1,135,026
Jennison Associates LLC2,358,587$129.7M0.1%−981,905
Jupiter Topco LLC2,242,106$123.3M0.1%New
Hood River Capital Management LLC2,224,788$122.4M0.9%+175,109
Driehaus Capital Management LLC2,205,618$121.3M0.7%+285,385
Eventide Asset Management, LLC2,111,410$116.1M1.6%−85,975
Polar Capital Holdings Plc1,878,580$103.3M0.3%−105,048
Holocene Advisors, LP1,755,978$96.6M0.2%−134,949
Adage Capital Partners Gp, L.l.c.1,731,402$95.2M0.1%+1,031,402
Morgan Stanley1,538,776$84.6M0.0%+1,319,749
Woodline Partners LP1,500,470$82.5M0.3%No change
Goldman Sachs Group Inc1,411,477$77.6M0.0%+12,494
Capital World Investors1,160,409$63.8M0.0%+31,657

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Yahoo FinanceSRRK quote
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59